Secondary Logo

Journal Logo

Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa

the implementation science frontier

Joseph Davey, Dvora L.a,b,c,d; Bekker, Linda-Gaile; Gorbach, Pamina M.b; Coates, Thomas J.c; Myer, Landona,d

doi: 10.1097/QAD.0000000000001604
OPINION
Free

aDivision of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa

bDepartment of Epidemiology, Fielding School of Public Health

cDivision of Infectious Disease and Center for World Health, David Geffen School of Medicine, University of California, Los Angeles, California, USA

dCentre for Infectious Disease Epidemiology and Research

eDesmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Correspondence to Dvora L. Joseph Davey, Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa. Tel: +27 829430578; e-mail: dvoradavey@ucla.edu

Received 2 May, 2017

Revised 5 July, 2017

Accepted 6 July, 2017

Back to Top | Article Outline

Introduction

HIV acquisition during pregnancy and postpartum periods remains high despite increased access to and initiation of antiretroviral therapy (ART) in Sub-Saharan Africa [1–5]. There are biological and behavioural factors that drive high HIV incidence during pregnancy and breastfeeding periods such as hormonal changes that alter genital mucosal surfaces, and frequent condomless sex with HIV-infected partners or partners of unknown serostatus [3,6–9]. Maternal seroconversion during pregnancy and breastfeeding contributes significantly toward paediatric HIV infections in Sub-Saharan Africa [3,10].

Oral preexposure prophylaxis (PrEP) efficacy in preventing HIV acquisition has been demonstrated in four randomized control trials among heterosexual men, women, serodiscordant couples, injecting drug users, and MSM when PrEP is used as directed [11–14]. Currently, PrEP is one of the only female-controlled method that is effective for preventing HIV acquisition. However, PrEP trials excluded pregnant women from enrolment, and those who were pregnant during these studies were discontinued from PrEP [11,14]. A recent systematic review demonstrated that PrEP was not associated with increased pregnancy-related adverse events, and no studies have found adverse effects among infants exposed to tenofovir disoproxil fumarate as part of treatment for HIV-infected women during pregnancy [15–19] or breastfeeding [15,20,21]. In addition, our studies in South Africa demonstrated that the use of tenofovir during pregnancy was not associated with adverse events among infants [19,22].

PrEP adherence has been low during clinical trials of women. In the Preexposure Prophylaxis Trial for HIV Prevention among African Women (FEM-PrEP) and Vaginal and Oral Interventions to Control the Epidemic (VOICE) trials, PrEP was not effective at preventing HIV acquisition among women in Eastern and Southern Africa because of low drug exposure (tenofovir was detected in plasma in fewer than one-third of participants) [23–25]. Pregnant and breastfeeding women may have improved initiation and adherence to PrEP because of the desire to prevent vertical HIV transmission. However, future studies need to consider how best to increase adherence.

Part of the difficulty in preventing perinatal and postpartum HIV acquisition is that pregnant and breastfeeding women are oftentimes at risk of other health problems in addition to HIV. Prior studies have shown that over half of pregnancies in African women may be unplanned [2,4]. This combined with multiple partners, condomless sex, transactional sex, substance use, sex-based violence, and rape, all compound the challenges of addressing the need for effective female-controlled interventions to prevent HIV, but also to address the complexities of adherence and retention in the face of such clusters of risk.

In our view, PrEP is a public health priority in settings of high HIV incidence. This is especially true during periconception, pregnancy, and breastfeeding in South Africa where HIV incidence is high and the probability of vertical transmission is highest when women seroconvert and are viremic. There is an urgent need for operations research to evaluate how best to provide PrEP to pregnant and breastfeeding women in settings of high HIV incidence, including how to ensure optimal adherence. We advocate that the field move beyond clinical trials to focus on operations research to evaluate how best to operationalize PrEP delivery in pregnancy and breastfeeding adolescent girls and women, recognizing the high-risk nature of this group. We review the operational issues that need to be addressed and evaluated to ensure that PrEP delivery is effective at preventing HIV acquisition during pregnancy and lactation in high HIV incidence communities.

Back to Top | Article Outline

Integrating preexposure prophylaxis delivery and counselling into antenatal and postnatal care

Prior PrEP studies have not included pregnant women; thus, we do not know about how to integrate PrEP delivery and counselling into antenatal and postnatal care. Similar to operational research that helped optimize delivery of ART to pregnant and breastfeeding women [26,27], we need additional studies that operationalize how best to deliver PrEP (e.g. through pharmacies, in community pick-up points, or within clinical visits), monitor PrEP adherence, and counsel pregnant and breastfeeding women to optimize PrEP initiation, retention, and effective use during periods of condomless sex with HIV-infected partners or partners of unknown serostatus. Notably, prevention within serodiscordant couples in an era of multicomponent prevention requires attention to both partners, and development of synergies between ART initiation and retention for HIV-infected partners and PrEP for HIV-negative partners to avoid missing prevention opportunities. Further, integrating PrEP into postnatal care may be more complex, because of the different care providers and locations. For example, postnatal care, well baby visits, and immunization visits may all be separate providers in different locations from antenatal care providers. Operations research studies are urgently required to understand the role of peer educators, counsellors, nurses, and doctors in promoting PrEP use, and ensuring adherence through vulnerable periods of pregnancy and lactation.

We hypothesize that mothers’ risk perceptions, risk behaviours, and concerns of protecting her child during and after pregnancy may be powerful drivers of PrEP initiation and adherence, similar to what we have found in prevention of mother to child transmission programs [28]. However, the ongoing concern about taking medication during pregnancy, and beliefs about side-effects among infants, may supersede women's concern about HIV acquisition. In this context, operations research is needed to determine how best to operationalize PrEP delivery to women who need it. Specifically, what cadre of providers should be trained to provide PrEP to pregnant women. Table 1 lists some of the essential operations research questions for optimal PrEP efficacy to prevent maternal HIV acquisition.

Table 1

Table 1

Back to Top | Article Outline

Optimal preexposure prophylaxis adherence during periconception, pregnancy, and postpartum periods

PrEP efficacy requires adherence during periods of sexual activity and adherence requires PrEP access, awareness, and counselling. Currently, a major obstacle in the PrEP field is effective use, especially among women during at-risk periods before periods of sexual activity [23,24,29–32]. Little is known about how to successfully engage and retain women trying to conceive, as well as pregnant and breastfeeding women living in high-burden settings in PrEP care, nor how to effectively support adherence and persistence to PrEP in this population [33]. PrEP adherence in this population must be understood within the context of highly variable risk for HIV infection during pregnancy and breastfeeding [29].

Prevention of mother-to-child transmission may also make women taking PrEP more acceptable to their partner(s), family, as well as health providers. Prior studies demonstrated an association between having perceived HIV risk and improved PrEP adherence [26]. Improving knowledge about the increased risk of HIV acquisition during pregnancy and breastfeeding could possibly contribute to improved PrEP initiation and adherence. Furthermore, provider barriers may include perceptions that PrEP will lead to more risk or more condomless sex. More research is needed on what kinds of messages, and from which types of individuals or providers, are needed to ensure optimal PrEP adherence in periconception, pregnant, and breastfeeding women. Novel approaches are needed to understand and evaluate provider and patient-level barriers to the PrEP cascade in periconception, pregnancy, and lactation periods in high HIV incidence countries.

Back to Top | Article Outline

Targeting preexposure prophylaxis to at-risk women in periconception, pregnancy, and postpartum periods

Not all HIV-uninfected African pregnant and lactating women will benefit from taking PrEP. The WHO set the threshold of ensuring PrEP availability where HIV incidence is three or more per 1000 person-years [34]. In communities where HIV incidence is lower than three per 1000 person-years, it may make sense to target PrEP delivery to those at highest risk. A recent study, developed a risk score to predict maternal HIV acquisition in Kenya [31]. Risk scores are one method for reaching pregnant women at high risk of HIV acquisition, but, there is a need to identify other ways to reach target populations. For example, a risk score that is dependent on self-reported measures of behaviour may underestimate the true HIV acquisition risk, and not all women have insight into their partners’ risk-taking behaviours. The generalizability of risk prediction method requires careful consideration as part of future operations research to understand the role of targeting PrEP in different contexts [35].

Back to Top | Article Outline

Preexposure prophylaxis for adolescent girls and young women at high risk of HIV acquisition

In Sub-Saharan Africa, an estimated 7000 new HIV infections are occurring weekly in adolescent girls and young women [36]. Further, adolescent girls have high pregnancy rates in South Africa. Approximately, 1.6% of 15-year-old, 3.7% of 16-year-old, and 7% of 17-year-old girls were pregnant in 2013 [36]. Prior studies have demonstrated significant challenges providing PrEP to adolescent girls and young women and the issues around providing PrEP to pregnant and postpartum women are unknown, which makes pregnant and postpartum adolescents and young women a particularly vulnerable group [24,37]. Operations research should include adolescent pregnant girls to evaluate predictors of PrEP initiation, retention, and adherence among this particular population which may differ from adult pregnant and breastfeeding women [2]. Including adolescent girls will increase the validity and generalizability of those interventions. Finally, it would be unethical to not provide pregnant and breastfeeding adolescent girls and young women with PrEP and include them in PrEP studies [2].

In conclusion, in light on current knowledge on the safety of PrEP in pregnancy and breastfeeding, and the persistent high HIV incidence during these vulnerable periods, PrEP in pregnancy and breastfeeding is critical to the elimination of maternal to child HIV transmission. There is an urgent need for operations research to evaluate how best to provide PrEP to pregnant and breastfeeding women in settings of high HIV incidence. Specifically, pilots and operations research should focus on evaluating how best to deliver PrEP in periconception, antenatal, and postnatal care, who should be targeted for PrEP delivery (including how best to reach and manage adolescent girls and young women), and how to address the barriers to PrEP effectiveness, and promote optimal adherence given the multifactorial challenges these women face in staying HIV negative. Such studies are required to ensure that when PrEP in pregnancy and breastfeeding programs are rolled out, they are utilizing and adapting the best of current knowledge in the field to ensure optimal impact.

Back to Top | Article Outline

Acknowledgements

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4-8 weeks postpartum in South Africa 2011-2012: a national population-based evaluation. PLoS One 2015; 10:e0125525.
2. Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mlotshwa M, Madlala BT, Abdool Karim SS. HIV incidence in young girls in KwaZulu-Natal, South Africa: public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav 2012; 16:1870–1876.
3. Johnson LF, Stinson K, Newell ML, Bland RM, Moultrie H, Davies MA, et al. The contribution of maternal HIV seroconversion during late pregnancy and breastfeeding to mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 2012; 59:417–425.
4. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001608.
5. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366:1182–1188.
6. Keating MA, Hamela G, Miller WC, Moses A, Hoffman IF, Hosseinipour MC, et al. High HIV incidence and sexual behavior change among pregnant women in Lilongwe, Malawi: implications for the risk of HIV acquisition. Plos One 2012; 7:e39109.
7. Lawoyin TO, Larsen U. Male sexual behaviour during wife's pregnancy and postpartum abstinence period in Oyo State, Nigeria. J Biosoc Sci 2002; 34:51–63.
8. Onah HE, Iloabachie GC, Obi SN, Ezugwu FO, Eze JN. Nigerian male sexual activity during pregnancy. Int J Gynaecol Obstet 2002; 76:219–223.
9. Peltzer K, Mlambo G. Sexual HIV risk behaviour and associated factors among pregnant women in Mpumalanga, South Africa. BMC Pregnancy Childbirth 2013; 13:57.
10. Humphrey JH, Marinda E, Mutasa K, Moulton LH, Iliff PJ, Ntozini R, et al. ZVITAMBO study group. Mother to child transmission of HIV among Zimbabwean women who seroconverted postnatally: prospective cohort study. BMJ 2010; 341:c6580.
11. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
12. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083–2090.
13. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587–2599.
14. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007; 2:e27.
15. Nachega JB, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2017; doi: 10.1097/QAI.0000000000001359. [Epub ahead of print].
16. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, et al. Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA 2014; 312:362–371.
17. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis (PrEP) for all populations: A systematic review and meta-analysis. AIDS 2016; 30:1973–1983.
18. Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol 2010; 37:907–927.
19. M le Roux S, Jao J, Brittain K, Phillips TK, Olatunbosun S, Ronan A, et al. Tenofovir exposure in utero and linear growth in HIV exposed, uninfected infants: a prospective study. AIDS 2016; Oct 14. PMID: 27755111. No PMC ID.
20. Mugwanya KK, Hendrix CW, Mugo NR, Marzinke M, Katabira ET, Ngure K, et al. Preexposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 2016; 13:e1002132.
21. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55:1315–1317.
22. Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis 2016; 62:1604–1609.
23. Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP Study Group. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2014; 66:324–331.
24. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, et al. Differences in cumulative exposure and adherence to tenofovir in the VOICE, iPrEx OLE, and PrEP demo studies as determined via hair concentrations. AIDS Res Hum Retrovir 2017; doi: 10.1089/aid.2016.0202.
25. Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS One 2015; 10:e0125458.
26. Sturke R, Siberry G, Mofenson L, Watts DH, McIntyre JA, Brouwers P, Guay L. Creating sustainable collaborations for implementation science: the case of the NIH-PEPFAR PMTCT implementation science alliance. J Acquir Immune Defic Syndr 2016; 72 (suppl 2):S102–S107.
27. Newman Owiredu M, Bellare NB, Chakanyuka Musanhu CC, Oyelade TA, Thom EM, Bigirimana F, et al. Building health system capacity through implementation research: experience of INSPIRE: a multi-country PMTCT implementation research project. J Acquir Immune Defic Syndr 2017; 75 (suppl 2):S240–S247.
28. Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav 2013; 17:2143–2155.
29. Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS 2015; 29:1277–1285.
30. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73:691–705.
31. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron R, et al. A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis 2017; 64:751–758.
32. Corneli A, Perry B, McKenna K, Agot K, Ahmed K, Taylor J, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr 2016; 71:452–461.
33. Heffron R, Pintye J, Matthews LT, Weber S, Mugo N. PrEP as peri-conception HIV prevention for women and men. Curr HIV/AIDS Rep 2016; 13:131–139.
34. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection—recommendations for a public health approach—second edition, 2016. Geneva, Switzerland: World Health Organization, 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/. No PMC ID. Accessed June 1, 2017
35. Debray TP, Damen JA, Snell KI, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ 2017; 356:i6460.
36. Kirby T. Targeting HIV prevention to young women in Africa. Lancet 2016; 388:2579.
37. Hosek S, Celum C, Wilson CM, Kapogiannis B, Delany-Moretlwe S, Bekker LG. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa. J Int AIDS Soc 2016; 19 7:21107(Suppl 6).
Keywords:

breastfeeding; HIV prevention; pregnant; preexposure prophylaxis; Sub-Saharan Africa

Copyright © 2017 Wolters Kluwer Health, Inc.